OpenLobby.EU

Pfizer Inc.

PFE

Pfizer is a global biopharmaceutical company that discovers, develops, and manufactures medicines and vaccines to improve lives worldwide.

Lobbying Activity

Meeting with Andi Cristea (Member of the European Parliament) and

25 Nov 2025 · Recent developments in EU-US trade policy

Meeting with Hildegard Bentele (Member of the European Parliament) and

8 Oct 2025 · Biotech

Response to Commission Communication on a EU Cardiovascular Health Plan

16 Sept 2025

Pfizer Warns EU Critical Medicines Act Risks Undermining Innovation

4 Jul 2025
Feedback on — EU regulation to strengthen pharmaceutical supply chains and prevent medicine shortages.
Their ask — Pfizer requests risk-based measures and comprehensive impact assessment before implementation. They advocate for strategic partnerships and diversified trade rather than local production requirements. The company opposes expanding joint procurement beyond health emergencies and seeks narrower focus on Union List medicines.1234
How it helps them — This would preserve their global supply chain flexibility and prevent costly localization requirements.567
Who loses — European manufacturers lose advantage as rules favor Pfizer's global production model over local supply.89
Response to: Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL laying a framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest, and amending Regulation (EU) 2024/795

Meeting with András Tivadar Kulja (Member of the European Parliament, Shadow rapporteur for opinion)

1 Jul 2025 · Critical medicines act

Pfizer Calls for Faster Clinical Trials and Enhanced Biotech Funding

11 Jun 2025
Feedback on — EU regulation to accelerate biotechnology innovation from laboratory to market.
Their ask — Pfizer requests faster clinical trial approvals through early scientific dialogues and reinforced ethics review provisions. They want dedicated funding programs for biotech SMEs and support for specialized biohubs. They also seek expanded use of real-world data in regulatory decisions.123
How it helps them — This would speed up drug approvals and reduce research costs through public funding.45
Response to: Proposal for a Regulation of the European Parliament and Council to foster biotechnology in Europe

Meeting with Margarita De La Pisa Carrión (Member of the European Parliament) and Asociación Española Contra el Cáncer

11 Jun 2025 · Beating Cancer Plan

Meeting with Aurelijus Veryga (Member of the European Parliament)

23 Apr 2025 · Joint procurement in the Critical Medicines Act – impact on access and EU competitiveness

Meeting with Tomislav Sokol (Member of the European Parliament)

23 Apr 2025 · Health policy

Pfizer urges EU life sciences investment to reverse innovation decline

16 Apr 2025
Feedback on — EU strategy to boost life sciences competitiveness, innovation, and reduce dependencies.
Their ask — Pfizer requests stronger intellectual property protections, streamlined regulatory frameworks, and development of biohubs connecting universities and companies. They emphasize positioning healthcare as strategic investment rather than cost, and promoting sustainable procurement without discriminatory 'made in Europe' provisions.1234
How it helps them — This would attract pharmaceutical R&D investment back to Europe and reduce regulatory compliance burdens.56
Who loses — European manufacturers lose if 'made in Europe' provisions are excluded from public procurement.7
Response to: Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions on the “Strategy for European Life Sciences”

Meeting with Pascal Canfin (Member of the European Parliament, Shadow rapporteur) and Inter Ikea Systems BV

16 Apr 2025 · Omnibus I

Meeting with Kristoffer Storm (Member of the European Parliament) and Affordable Medicines Europe

9 Apr 2025 · Pharmaceutical Industry

Meeting with Niels Flemming Hansen (Member of the European Parliament)

9 Apr 2025 · Lægemiddelspakke

Meeting with Carlo Ciccioli (Member of the European Parliament, Shadow rapporteur)

7 Apr 2025 · ITRE INI on the future of Biotechnologies and Biomanufacturing

Meeting with Stéphane Séjourné (Executive Vice-President) and

21 Mar 2025 · - Marché intérieur - Compétitivité - Sécurité économique - Simplification - Relation USA / Europe

Meeting with Billy Kelleher (Member of the European Parliament)

18 Mar 2025 · Pharmaceutical strategy and trade

Meeting with Eva Maydell (Member of the European Parliament)

18 Mar 2025 · EU-US Relations

Meeting with Tomislav Sokol (Member of the European Parliament)

18 Mar 2025 · Health policy

Pfizer Urges Risk-Based Approach to EU Critical Medicines Supply

27 Feb 2025
Feedback on — EU regulation to address supply chain vulnerabilities and reduce dependencies for critical medicines.
Their ask — Pfizer requests measures that are risk-based, proportionate, and sustainable. They advocate for recognizing that production outside Europe does not inherently constitute a vulnerability and support harmonized EU approaches for contingency stocks rather than national stockpiling requirements.123
How it helps them — This would preserve their global manufacturing network and avoid costly national stockpiling requirements.45
Who loses — Member states lose autonomy over medicine stockpiling and may face greater dependency on global supply chains.6
Response to: Critical Medicines Act

Meeting with Stine Bosse (Member of the European Parliament) and Greater Copenhagen EU Office

13 Dec 2024 · European health policy

Meeting with Valérie Hayer (Member of the European Parliament) and L'Oréal

10 Dec 2024 · Évènement Politico - Divers

Meeting with András Tivadar Kulja (Member of the European Parliament)

14 Nov 2024 · Biotech Act, medicines shortages

Meeting with Niels Flemming Hansen (Member of the European Parliament)

26 Sept 2024 · Priorities for the mandate

Meeting with Ruggero Razza (Member of the European Parliament) and Vaccines Europe

17 Jul 2024 · Incontro conoscitivo e scambio di vedute sul mandato del Parlamento europeo

Meeting with Stine Bosse (Member of the European Parliament)

17 Jul 2024 · EU health policy

Meeting with Jörgen Warborn (Member of the European Parliament) and Almega

17 Jul 2024 · Trade

Meeting with Wouter Beke (Member of the European Parliament)

16 Jul 2024 · Health policy / internal market, freedom of mobility, digital and wider consumer policies

Meeting with Jörgen Warborn (Member of the European Parliament)

25 Jan 2024 · TRIPS

Pfizer warns EU pharmaceutical reforms risk undermining innovation leadership

31 Oct 2023
Feedback on — EU revision of pharmaceutical legislation to improve medicine access and affordability.
Their ask — Pfizer supports streamlined regulatory processes and antimicrobial incentives but opposes making regulatory data protection contingent on launching across all 27 Member States. They argue this ignores fragmented market access dynamics and places entire burden on companies rather than addressing root causes in national reimbursement processes. On supply security, they want definitions to reference medical demand and oppose mandatory shortage prevention plans for all medicines as disproportionate and resource-intensive.12
How it helps them — This would preserve their regulatory data protection without requiring launch commitments across fragmented markets.3
Who loses — Patients in smaller EU markets lose leverage for faster medicine launches.
Response to: Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the Union code relating to medicinal products for human use, and repealing Directive 2001/83/EC and Directive 2009/35/EC

Meeting with Fabio Massimo Castaldo (Member of the European Parliament)

24 Oct 2023 · Sickle Cell Disease landscape and challenges in the Europe

Meeting with István Ujhelyi (Member of the European Parliament)

24 Oct 2023 · Sickle Cell Disease

Meeting with Geoffroy Didier (Member of the European Parliament, Shadow rapporteur)

18 Oct 2023 · Compulsory licensing

Meeting with Catherine Amalric (Member of the European Parliament, Shadow rapporteur)

16 Oct 2023 · Reform of the EU pharmaceutical legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and

13 Oct 2023 · Directive on Medicinal products for human use

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

6 Oct 2023 · Directive on Medicinal products for human use

Meeting with Tomislav Sokol (Member of the European Parliament, Shadow rapporteur)

3 Oct 2023 · Pharmaceutical legislation

Meeting with Tomislav Sokol (Member of the European Parliament, Shadow rapporteur)

19 Sept 2023 · Pharmaceutical legislation

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur)

7 Sept 2023 · Directive Medicinal products for human use

Response to Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on compulsory licensing for crisis management and amending Regulation (EC) 816/2006

28 Jul 2023

Meeting with Pernille Weiss-Ehler (Member of the European Parliament, Rapporteur) and

11 Jul 2023 · Directive on Medicinal products for human use

Meeting with Mairead McGuinness (Commissioner) and

2 Mar 2023 · Introductory meeting

Meeting with Sirpa Pietikäinen (Member of the European Parliament)

15 Feb 2023 · EU’s general pharmaceutical legislation and EU Regulation on Orphan Medicinal Products (OMPs)

Meeting with Kathleen Van Brempt (Member of the European Parliament, Committee chair)

26 Jan 2023 · Decision by the COVI Committee Coordinators on the request to withdraw long-term access badges of Pfizer (APA)

Meeting with Kathleen Van Brempt (Member of the European Parliament, Committee chair)

24 Jan 2023 · Decision by the COVI Committee Coordinators on the request to withdraw long-term access badges of Pfizer (APA)

Meeting with Kathleen Van Brempt (Member of the European Parliament, Committee chair)

30 Nov 2022 · Participation of dr. Albert Bourla, CEO of Pfizer, in a second hearing

Meeting with Kathleen Van Brempt (Member of the European Parliament, Committee chair)

25 Nov 2022 · COVID-19: deelname Dr Bourla aan hoorzitting van de COVI-commissie - APA

Meeting with Dolors Montserrat (Member of the European Parliament, Rapporteur)

8 Nov 2022 · Lessons learned on impact of COVID-19 pandemic

Meeting with Nicolás González Casares (Member of the European Parliament, Shadow rapporteur)

25 Oct 2022 · medicines

Meeting with Stella Kyriakides (Commissioner) and

12 Oct 2022 · Exchange on-going cooperation; Europe's Beating Cancer plan - exchange on innovation in the future of cancer treatment and care

Meeting with Andreas Glück (Member of the European Parliament, Committee chair)

4 Oct 2022 · COVID19 lessons learned

Meeting with Margaritis Schinas (Vice-President)

9 Sept 2022 · Pharma Strategy

Meeting with Karin Karlsbro (Member of the European Parliament) and

17 May 2022 · Pharmaceuticals

Meeting with Cyrus Engerer (Member of the European Parliament) and Novartis International AG

3 Dec 2021 · Joint Procurement of Medicines

Meeting with Cyrus Engerer (Member of the European Parliament)

3 Dec 2021 · Pharmaceutical Strategy

Meeting with Ursula von der Leyen (President)

26 Nov 2021 · Meeting with CEO of Pfizer

Meeting with Caroline Boeshertz (Cabinet of Executive Vice-President Valdis Dombrovskis), Elina Melngaile (Cabinet of Executive Vice-President Valdis Dombrovskis), Kevin Keary (Cabinet of Executive Vice-President Valdis Dombrovskis) and

26 Oct 2021 · Pharmaceutical sector – trade related issues

Meeting with Giorgos Rossides (Cabinet of Commissioner Stella Kyriakides), Roberto Reig Rodrigo (Cabinet of Commissioner Stella Kyriakides)

18 Oct 2021 · Call with Pfizer’s Regional President for Vaccines, Mr. Sinan Atlig, to discuss the implementation of COVID-19 vaccines Advance Purchase Agreement

Meeting with Nicolae Ștefănuță (Member of the European Parliament)

15 Oct 2021 · Meeting regarding Pfizer vaccine

Meeting with Margaritis Schinas (Vice-President) and

16 Jun 2021 · Supply chains for medicines

Meeting with Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton)

7 May 2021 · Site visit and assessment of production capacity and supply chain

Pfizer Warns Against Regulatory Changes, Seeks IP Protections

27 Apr 2021
Feedback on — Revision of EU pharmaceutical legislation covering market authorization and innovation incentives.
Their ask — Pfizer opposes changes to intellectual property incentives, arguing root causes of access problems lie beyond EU competences. They request a High-Level Forum on access, transferable exclusivity extensions for antimicrobials, and exemption of ATMPs from GMO legislation.123
How it helps them — This would preserve their intellectual property protections and maintain pricing flexibility across markets.45
Who loses — Patients in poorer EU countries lose affordable access as pricing flexibility perpetuates inequalities.6
Response to: Evaluation and Revision of Regulation (EC) No 726/2004 and Directive 2001/83/EC

Meeting with Thierry Breton (Commissioner)

10 Apr 2021 · Vaccine production and deliveries

Meeting with Maurits-Jan Prinz (Cabinet of Commissioner Thierry Breton)

7 Apr 2021 · Vaccine delivery schedule for Q2 2021

Meeting with Thierry Breton (Commissioner)

21 Feb 2021 · COVID-19 vaccines production

Meeting with Ursula von der Leyen (President) and

31 Jan 2021 · Meeting with CEOs of the pharmaceutical companies with which the Commission has signed Advance Purchase Agreements

Response to Proposal for an EP and Council Regulation on orphan and paediatric medicinal products

4 Jan 2021

Response to Commission Communication on a Pharmaceutical Strategy- Ensuring sustainable innovation and the availability and affordability of medicines and medical technologies for citizens

6 Jul 2020

Response to Commission Communication on Europe’s Beating Cancer Action Plan

2 Mar 2020

Meeting with Nele Eichhorn (Cabinet of Vice-President Cecilia Malmström)

27 Nov 2018 · EU-US relations, trade aspects of Brexit

Meeting with Vytenis Andriukaitis (Commissioner) and

29 Nov 2017 · Pharmaceutical incentives, antimicrobial resistance

Meeting with Jyrki Katainen (Vice-President) and

21 Nov 2017 · Internal Market's industrial property legal framework relating to supplementary protection certificates (SPC) and patent research exemptions; innovation in the pharmaceutical industry

Meeting with Pierre Moscovici (Commissioner) and

1 Sept 2017 · Exchange of views on the Italian and euro zone economies and priorities for reform

Meeting with Bernardus Smulders (Cabinet of First Vice-President Frans Timmermans) and

14 Jan 2016 · AECA Round-Table on “Dealing with Regulatory Burden

Meeting with Annika Nowak (Cabinet of Commissioner Vytenis Andriukaitis)

2 Mar 2015 · Access to innovative medicine

Meeting with Rolf Carsten Bermig (Cabinet of Commissioner Elżbieta Bieńkowska)

27 Jan 2015 · Introductory meeting